证券代码：000950 证券简称：重药控股 公告编号：2023-075 重药控股股份有限公司 关于控股子公司2023年度第八期 超短期融资券发行结果公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 重药控股股份有限公司（以下简称"公司"）控股子公司重庆医药（集 团）股份有限公司发行超短期融资券已于2021年12月24日经中国银行间市场交 易商协会注册通过（《接受注册通知书》中市协注[2021]SCP533号），注册金 额为40亿元，注册额度自《接受注册通知书》落款之日起两年内有效。具体内 容详见公司于2022年1月14日在巨潮资讯网（www.cninfo.com.cn）披露的相关公 告。 重庆医药（集团）股份有限公司2023年度第八期超短期融资券于2023年8月 11日完成发行，募集资金已于2023年8月14日到账。现将发行结果公告如下： 2023年8月15日 | 名称 | 重庆医药（集团）股份有限公司 2023年度第八期超短期融资券 | 简称 | 23渝医药SCP008 | | --- | --- | --- | --- | | 代码 | 0123830 ...

证券代码：000950 证券简称：重药控股 编号：2023-011 | --- | --- | --- | |----------------|----------------------|----------------------------------------| | | 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位： | | | | | 西南证券、博时基金、相聚资本、华西证券 | | | 上市公司接待人员： | | | 活动参与人员 | | | | | 财务总监、董事会秘书 | 邱天 | | | 证券事务代表曹芳 | | | | 公司IR团队工作人员 | | | 时间 | 2023年7月17日-20 | 日 | | 地点 | 公司会议室 | | 形式 现场会议 1、公司十四五战略中"千亿"目标是如何细分的 公司业务仍以药品配送为主，占 600-700 亿，器械端 200 亿左右，中药、新兴业务等约 100 亿 ...

Group 1: Company Overview and Strategy - The company has established a commercial network covering 31 provinces, with over 200 subsidiaries as of the end of 2022 [2] - The strategy focuses on "internal growth + external mergers," aiming to expand the national sales network and fill provincial market gaps [2] - The "14th Five-Year Plan" includes a target to develop a presence in 300 cities, enhancing competitive advantages and bargaining power [2] Group 2: Medical Equipment Growth - The company has formed a medical device division, managing both medical equipment and pharmaceuticals through dual-line management [3] - In 2022, the company advanced 8 SPD projects across Sichuan, Liaoning, Shaanxi, and Guangzhou, with over 110 companies involved in medical equipment business [3] - Future plans include focusing on niche markets such as orthopedics, assisted reproduction, and disinfection supply [3] Group 3: Sales and Distribution Channels - The company has approximately 7,000 secondary and above pure sales customers, with pure sales accounting for 80% of total sales [3] - The shift towards "pharmaceuticals + internet" and the externalization of prescription drugs will leverage the company's high-quality hospital sales network [3] Group 4: Financial Management and Challenges - The company faces longer receivable collection periods in the western region compared to the eastern region, primarily dealing with public hospitals [3] - Measures to optimize receivables include stricter assessments, controlling "two funds," and improving procurement management [3] - The company is addressing low gross margins and high debt ratios due to national procurement and medical insurance cost control policies [3] Group 5: Debt-to-Equity Conversion - The company plans to conduct debt-to-equity swaps to introduce long-term equity funding, aimed at repaying interest-bearing debts [3] - This initiative is expected to enhance capital strength and reduce the debt ratio, contributing to sustainable development [3]

证券代码：000950 证券简称：重药控股 编号：2023-009 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 类别 □新闻发布会 □路演活动 现场参观 □其他 （请文字说明其他活动内容） 参与单位： 华泰证券股份有限公司 海南旭日盛德资产管理有限公司 重庆穿石投资有限公司 天人舒泰基金 重庆环保产业私募股权投资基金管理有限公司 重庆先石投资管理有限公司 重庆博永私募证券投资基金管理有限公司 活动参与人员 重庆智道投资有限公司 海南盛世私募基金管理有限公司 重庆渝康私募股权投资基金管理有限公司 浙江纯原基金 北海恒睿信私募投资基金 民生证券股份有限公司 上市公司接待人员： 证券事务代表 曹芳 公司 IR 团队工作人员 时间 2023 年 6 月 19 日 地点 公司会议室 1 重药控股股份有限公司投资者关系活动记录表 形式 现场会议 一、介绍公司战略 公司"十四五"的战略规划为"一千两双三百城、三化四能 五路军"。"一千"指力争到 2025 年实现收入超千亿；"两双"指 内生、外延双轮驱动；"三百城"指实现全国商业网络的覆盖， 布局 300 余个区域；"三化"指批零一体化、产品全面化 ...

Group 1: Strategic Planning - The company's "14th Five-Year" strategic plan aims for a sales scale exceeding 100 billion yuan, driven by both organic growth and external expansion [2] - The plan includes completing layouts in 300 cities across the country, focusing on integrated retail and wholesale, product diversification, and business digitization [2] Group 2: Digital Business Development - The company emphasizes digital transformation, investing in various management systems such as ERP and WMS to enhance operational efficiency [3] - It has established its own e-commerce platform, "Zhongyao Cloud Business," providing 24-hour one-stop procurement services and online health services [3] Group 3: Accounts Receivable Risk Management - The company acknowledges the high accounts receivable typical in the pharmaceutical industry, primarily from public hospitals, but considers the repayment risk to be low [3] - Measures have been implemented to strengthen accounts receivable management and improve cash flow from operations [3] Group 4: Financial Cost Management - The company currently relies heavily on debt financing, resulting in high financial costs, with plans to optimize its financing structure to reduce these costs [3] Group 5: Mergers and Acquisitions - Previous investments and acquisitions during the "13th Five-Year" period have yielded positive results, with future plans to accelerate national network layout in line with the "300 Cities" strategy [3]

证券代码：000950 证券简称：重药控股 编号：2023-007 | --- | --- | --- | |----------------|--------------|----------------------------| | | 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | 活动参与人员 线上参与公司重药控股 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 19 日 下午 15:00-16:00 地点 "重药控股投资者关系"微信小程序 董事长：袁泉先生 上市公司接待人 总经理：刘伟先生 员姓名 独立董事：章新蓉女士 财务总监兼董事会秘书：邱天先生 1、问：恭喜！在您领导下，公司稳定发展，取得不俗成 绩。回顾这几年，公司对普通投资者的回报与公司的财务费用， 反差明显。大家理解，但可能不代表支持。请问贵司是否有具 体地改善措施？顺便能否分享一下您作为一名投资者，您的感 受与心得？谢谢！ 交流内容及具体 答：公司重 ...

证券代码：000950 证券简称：重药控股 公告编号：2023-054 关于举行2022年度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 重药控股股份有限公司（以下简称"公司"）已于2023年4月27日在巨潮资讯 网（http://www.cninfo.com.cn/）上披露了《2022年年度报告》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年5 月19日（星期五）下午15:00至16:00时在"重药控股投资者关系"小程序举行2022 年度业绩说明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆"重 药控股投资者关系"小程序参与互动交流。为广泛听取投资者的意见和建议，提 前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"重药控股投资者关系"； 参与方式二：微信扫一扫以下二维码： 重药控股股份有限公司 员可能进行调整。） 敬请广大投资者积极参与。 特此公告 重药控股股份有限公司董事会 2023 年 5 月 12 日 投资者依据提示，授权登入"重药控股投资者关系"小程序， ...

证券代码：000950 证券简称：重药控股 编号：2023-006 | --- | --- | --- | |----------------|----------------------------|--------------------------------| | | 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | 参与单位及人员： | | | | 西南证券：杜向阳、钱彦君 | | | | 德邦证券：张绍辉 | | | | 华夏基金：胥梦缘 | | | | 华泰证券：孔垂岩、王殷杰 | | | | 华安证券：熊智军、权炫瑞 | | | | 兴业证券：王声亮 | | | | 国金证券：王大伟 | | | | 华鑫证券：胡博新 | | | | 大成基金：王敏杰 | | | 活动参与人员 | | | | | 汐泰投资：董函 | | | | 银河证券：张立婧 | | | | 银华基金：孙昊阳、戴方贤 | | | | 中欧基金：任逸 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥19,620,276,794.03, representing a 23.56% increase compared to ¥15,878,655,477.15 in the same period last year[7]. - Net profit attributable to shareholders was ¥166,044,332.35, up 48.40% from ¥111,888,762.43 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥149,020,220.06, a significant increase of 149.12% from ¥59,818,669.95 in the previous year[7]. - The total operating revenue for Q1 2023 was CNY 19,620,276,794.03, an increase of 23.3% compared to CNY 15,878,655,477.15 in the same period last year[36]. - The net profit for Q1 2023 reached CNY 231,764,045.24, representing a 60.7% increase from CNY 144,327,904.72 in Q1 2022[38]. - The total comprehensive income for the period amounted to ¥231,764,045.24, compared to ¥144,327,904.72 in the previous period, reflecting a significant increase[39]. - The net income attributable to the parent company was ¥166,044,332.35, up from ¥111,888,762.43 year-over-year[39]. - Basic and diluted earnings per share both increased to ¥0.10 from ¥0.06 in the previous period[39]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥60,795,703,509.72, reflecting a 6.30% increase from ¥57,191,648,432.88 at the end of the previous year[7]. - The total liabilities as of Q1 2023 amounted to CNY 47,669,938,424.95, an increase from CNY 44,481,256,335.77 in the previous year[36]. - The total liabilities increased, with short-term borrowings reaching 15,105,286,336.39 RMB compared to 14,772,107,320.83 RMB previously[27]. - The company reported a significant increase in other receivables, which rose to 1,331,638,771.54 RMB from 1,131,343,680.69 RMB[27]. Cash Flow - The net cash flow from operating activities was -¥3,093,724,213.10, a 2.07% improvement from -¥3,159,107,305.23 in the previous year[19]. - The cash inflow from operating activities was CNY 18,152,138,655.52, compared to CNY 15,384,982,283.54 in the previous year, marking an increase of 18.2%[32]. - The net cash flow from investing activities decreased by 54.10% year-on-year, primarily due to a reduction in the amount from the sale of stock in International Potash[20]. - The net cash flow from financing activities decreased by 48.49% year-on-year, mainly due to an increase in the repayment of external financing as part of debt structure adjustments[20]. - The company reported a total cash outflow from operating activities of ¥21,245,862,868.62, compared to ¥18,544,089,588.77 in the previous year[43]. - Cash flow from investing activities showed a net inflow of ¥34,079,014.17, compared to ¥74,238,524.35 in the previous year[43]. - Cash flow from financing activities resulted in a net inflow of ¥1,330,850,572.46, down from ¥2,583,847,229.80 year-over-year[43]. Operational Highlights - Accounts receivable increased by 17.03% to ¥33,331,470,842.64, primarily due to concentrated settlements at the end of the previous year and new consolidated entities[12]. - Inventory rose by 4.55% to ¥8,220,329,741.18, driven by business expansion and stockpiling in response to procurement policies[13]. - The company continued to enhance its digital capabilities and organizational structure, leading to improved logistics and marketing capabilities[11]. - The company plans to accelerate its investment and acquisition projects to further expand its market presence[11]. - Research and development expenses increased significantly to CNY 1,497,098.60 from CNY 76,038.11, indicating a focus on innovation[38]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 43,504[21]. - The largest shareholder, Chongqing Pharmaceutical Health, holds 38.14% of the shares, totaling 664,900,806 shares[21]. Financial Expenses - The financial expenses increased by 25.37% to ¥328,473,998.37, mainly due to the issuance of asset securitization products[16]. - The company’s financial expenses rose to CNY 328,473,998.37 from CNY 262,001,662.52, reflecting increased borrowing costs[38]. Audit and Reporting - The company did not undergo an audit for the first quarter report[44]. - The report was released by the board of directors on April 27, 2023[45].

Financial Performance - The company's operating revenue for 2022 was ¥67.83 billion, an increase of 8.49% compared to ¥62.52 billion in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥952.28 million, a decrease of 5.29% from ¥1.01 billion in 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥875.40 million, an increase of 5.17% from ¥832.39 million in 2021[24]. - The net cash flow from operating activities was ¥285.83 million, up 14.26% from ¥250.16 million in 2021[24]. - Total assets at the end of 2022 were ¥57.19 billion, a 15.07% increase from ¥49.70 billion at the end of 2021[25]. - The company's basic earnings per share for 2022 was ¥0.55, down 5.17% from ¥0.58 in 2021[24]. - The weighted average return on equity for 2022 was 9.30%, a decrease of 1.48% from 10.78% in 2021[24]. - The total revenue for the reporting period reached 67.829 billion yuan, marking an overall increase of 8.49%[63]. - The pharmaceutical segment accounted for 84.20% of total revenue, with a year-on-year increase of 5.69%[66]. - The medical device segment achieved revenue of 9.514 billion yuan, growing by 26% year-on-year[69]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.6 CNY per 10 shares to all shareholders, with no stock bonus[4]. - The proposed cash dividend is ¥0.6 per 10 shares (including tax), with a total cash dividend amounting to ¥104,602,040.22, representing 100% of the distributable profit[174]. - The total number of shares for the dividend distribution is 1,743,367,337 shares, which will be adjusted if there are changes in the total share capital before the distribution[176]. - The company has a positive distributable profit of ¥106,164,101.60 available for distribution to shareholders[174]. - The independent directors have expressed their agreement with the profit distribution proposal, confirming its compliance with legal and regulatory requirements[173]. Business Strategy and Market Position - The company is focusing on digital healthcare services and expanding its professional pharmacy layout, targeting high-quality and specialized pharmaceutical services[35]. - The company is transitioning towards becoming a comprehensive supply chain service provider, covering 31 provinces and providing efficient services to various healthcare institutions[42]. - The company is actively optimizing its retail pharmacy network and accelerating the construction of prescription outflow platforms to capture more market share[39]. - The company is implementing a strategy of integrating wholesale and retail operations to enhance its market presence and service quality[45]. - The company aims to achieve over 100 billion RMB in revenue by 2025 as part of its "14th Five-Year" strategic plan[116]. - The company plans to establish over 1,000 retail pharmacies, focusing on DTP prescription pharmacies and community health pharmacies in the Sichuan-Chongqing region[122]. Research and Development - The company is actively investing in pharmaceutical R&D, emphasizing innovative development and collaboration with domestic and international research institutions[53]. - The company invested 5% of its revenue in R&D, focusing on innovative platforms and achieving over 60% of products with dual submissions in China and the U.S.[74]. - Research and development expenses increased by 25% in 2022, totaling 500 million RMB, to enhance product innovation[147]. - New product development is underway, with a focus on innovative pharmaceutical solutions to meet market demands[141]. Risk Management and Compliance - The company acknowledges potential risks related to industry competition, management, market conditions, and national policies[4]. - The company emphasizes adherence to legal and regulatory frameworks, ensuring the protection of shareholder rights and corporate governance[162]. - The company is implementing a comprehensive risk management system to ensure quality control and financial oversight[123]. Corporate Governance - The company has established an independent financial accounting system and maintains financial independence from its controlling shareholders[132]. - The company held six shareholder meetings in 2022, with participation rates ranging from 63.66% to 80.28%[134]. - The company has a clear commitment to uphold the legal obligations of shareholders and will not interfere with the business activities of the listed company[198]. - The company has established a governance structure that allows independent decision-making by the board and management[198]. Employee and Training Initiatives - The total number of employees at the end of the reporting period was 13,809, with 62 at the parent company and 13,747 at major subsidiaries[166]. - The company is committed to enhancing employee training through various programs, including "Mini MBA" and "New Employee Training"[169]. - A total of 20.85 million training sessions were conducted across the company and its subsidiaries in 2022[169]. Acquisitions and Investments - The company made significant equity investments, including a ¥245,195,000 acquisition for an 80% stake in Hunan Jiameng Pharmaceutical[102]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[141]. - The company has expanded its market presence through non-controlling mergers, including Chongqing Pharmaceutical Group Hunan Co., Ltd., enhancing the medical device distribution market[113]. Social Responsibility - The company actively participated in social responsibility initiatives, contributing a total of 44,200 yuan to consumption poverty alleviation efforts[195]. - The company issued four phases of rural revitalization notes, raising a total of 900 million yuan, part of which was used for drug procurement in 18 poverty alleviation areas[194].